Breakpoints19 Feb 2021

#34 – The New Scoop on Poop: Updates in the Management of C. difficile infections

Dr. Kevin Garey (@GareyKgarey), Dr. Kelly Reveles (@KellyReveles), Dr. Mandelin Cooper, and host Dr. Rachel Britt (@RachelBPharmD) discuss proposed updates of the IDSA-SHEA C. difficile guidelines, including: fidaxomicin over oral vancomycin as first-line therapy, the roles and logistical hurdles of fecal microbiota transplant, bezlotoxumab, and the pros and cons of prophylaxis.

Timestamps

1:16 - Panel introductions 3:19 - Fidaxomicin vs PO vancomycin for first occurrence 7:21 - Fidaxomicin cost effectiveness 11:26 - Factors to consider for health systems when considering switch to fidaxomicin 14:23 - Fidaxomicin vs PO vancomycin for recurrences 17:52 - Role of pulsed and tapered PO vancomycin 19:57 - Role of fecal microbiota transplant (FMT) 22:24 - Challenges of FMT and where pharmacy fits in 27:27 - Bezlotoxumab 31:54 - Feasibility issues with bezlotoxumab and strategies to address them 35:25 - CDI prophylaxis 40:28 - Stewardship's role in reducing C. difficile infections

References

Fidaxomicin Cost-effectiveness

Reveles KR, et al. Pharmacotherapy. 2017;37(12):1489-97.
Watt M, et al. Infection. 2016;44(5):599-606.
Cornely OA, et al. J Antimicrob Chemother. 2018;73(9):2529-39.
Rubio-Terres C, et al. Eur J Clin Microbiol Infect Dis. 2019;38(6):1105-11.

Bezlotoxumab

Wilcox MH, et al. N Engl J Med. 2017;376:305-17.
Oksi J, et al. Eur J Clin Microbiol Infect Dis. 2019;38(10):1947-52.
Hengel RL, et al. Open Forum Infect Dis. 2020;7(4):ofaa097.

Bezlotoxumab Cost-effectiveness

Salavert M, et al. Adv Ther. 2018;35(11):1920-34.
Prabhu VS, et al. Clin Infect Dis. 2018;66(3):355-62.

Primary prophylaxis

Pereiras MA, et al. Biol Blood Marrow Transplant. 2017; 23:S395.
Ganetsky A, et al. Clin Infect Dis. 2019;68(12):2003-2009.
Mullane KM, et al. Clin Infect Dis. 2019; 68(2):196–203.

Secondary prophylaxis

Carignan A, et al. Am J Gastroenterol. 2016;111:1834-1840.
Van Hise NW, et al. Clin Infect Dis. 2016;63:651-653.
Splinter et al. Ann Pharmacother. 2018;52:113-119.
Knight EM, et al. J Pharm Pract. 2019;:897190019825994.
Morrisette T, et al. Biol Blood Marrow Transplant. 2019;25(10):2091-2097.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(134)

#54 – Connecting with our Colleagues: COVID-19 Treatments in Community Pharmacies

Dr. Jennifer Morrow joins Dr. Rachel Britt (@RachelBPharmD) on this bonus episode of the Breakpoints podcast to discuss how the introduction of COVID-19 therapeutics and vaccines has affected communit...

18 Mar 202234min

#53 – Abscessus and fortuitum and avium, Oh My!: Updates and Controversies in NTM Management

Drs. Wendi Drummond and Jeff Pearson (@jeffpears0n) join Dr. Rachel Britt (@RachelBPharmD) on the Breakpoints podcast this week to discuss all things on non-tuberculosis mycobacteria pulmonary infecti...

18 Feb 20221h 11min

#52 – A Conversation with the Authors of IDSA Guidance on Treatment of AmpC, CRAB, and Stenotrophomonas

Drs. Pranita Tamma (@pranita_tamma) and Sam Aitken (@OncIDPharmd) are BACK on the podcast this week with Dr. Erin McCreary (@ErinMcCreary) to discuss IDSA guidance on AmpC producers, carbapenem-resist...

28 Jan 20221h 13min

#51 – A Conversation with the Authors of IDSA Guidance on Treatment of ESBL, CRE, and DTR Pseudomonas

Drs. Pranita Tamma (@pranita_tamma) and Sam Aitken (@OncIDPharmd), authors of the IDSA Guidance on gram-negative resistance, join Dr. Erin McCreary (@ErinMcCreary) for this exquisitely good episode to...

21 Jan 20221h 15min

#50 – Moving to the Algo-rhythm of IDWeek 2021: Highlights in SoMe and ASP

Episode Notes Drs. Timothy Gauthier (@IDstewardship) and Jillian Hayes (@thejillianhayes) join Dr. Zahra Kassamali Escobar (@zkePharmD) to recap some IDWeek 2021 highlights on social media and antimic...

17 Des 20211h 1min

#49 – A PGY-What Now? A Primer on ID Pharmacy Fellowships

Episode Notes Drs. Keith Rodvold and Taylor Morrisette (@TayMorrisette) join Dr. Julie Ann Justo (@julie_justo) to discuss ID pharmacy fellowships, their pros and cons compared to other post-graduate ...

3 Des 202151min

#48 – Aligning Goals: Antibiotics in End of Life Care

Drs. Molly Sinert and Jon Furuno join Dr. David Ha (@DHpharmd) to discuss the prevalence of antibiotic use and its harms and benefits in reducing suffering and providing comfort during end-of-life car...

19 Nov 20211h

#47 – A Nefarious Orchestra: Gram-Negative Resistance Mechanisms Part 2

From generating 150 liters-worth of E. coli to the first X-ray crystallography of an ESBL, Drs. Robert Bonomo, Ryan Shields (@ryankshields), and Erin McCreary (@ErinMcCreary) take a deep dive into bet...

29 Okt 20210s